SCHEMBL4730326

SCHEMBL4730326

CCOC(=O)c1cnn[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 2/20 0.51
PDE4D Q08499 1/20 0.44
ALPL P05186 1/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 2/20 0.42
HPGDS O60760 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 2/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22372176 0.86 ALDH1A1 (0.44) KMT2AALDH1A1MEN1RAB9ANPC1
SCHEMBL22372258 0.78 PHLPP2 (0.45) ALDH1A1RAB9AMAPTCYP1A2CYP2C19
SCHEMBL22372173 0.76 MMP1 (0.46) KMT2AALDH1A1MEN1PDE4DRAB9A
SCHEMBL210782 0.71
SCHEMBL8818379 0.70 ALDH1A1 (0.47) KMT2AALDH1A1MEN1RAB9ANPC1
SCHEMBL1720771 0.70 KDM4E (0.46) KMT2AALDH1A1MEN1PDE4DRAB9A
SCHEMBL1420098 0.70 ALDH1A1 (0.70) KMT2AALDH1A1MEN1PDE4DRAB9A
SCHEMBL970232 0.70 ALPL (0.57) KMT2AALDH1A1MEN1PDE4DALPL
SCHEMBL2052901 0.70 JMJD6 (0.52) KMT2AALDH1A1MEN1PDE4DALPL
SCHEMBL17146906 0.70 TSHR (0.59) KMT2AALDH1A1MEN1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
EP-4143195-B1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 EP disclosed
US-12264138-B2 Process for the preparation of microbiocidal oxadiazole derivatives SYNGENTA CROP PROTECTION AG (CH) 2025-04-01 US disclosed
US-20240376085-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2024-11-14 US disclosed
WO-2024208228-A1 NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) 2024-10-10 WO disclosed
EP-4408530-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 Janssen Pharmaceutica NV (BE) 2024-08-07 EP disclosed
US-12024524-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2024-07-02 US disclosed
CN-118119613-A Benzimidazoles as IL-17 modulators 詹森药业有限公司 2024-05-31 CN disclosed
CN-117886766-A Method for synthesizing 2-aryl-2H-benzotriazole compound by driving visible light and application thereof 汕头大学 2024-04-16 CN disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed
US-6165234-A FOR IMPARTING REVERSIBLE COLOR CHANGES TO WAXES AND CANDLES WHEN HEATED OR WHEN WAX MELTS OR WHEN THE CANDLE BURNS KANAKKANATT SEBASTIAN V (US) 2000-12-26 US disclosed
US-4826550-A Process for preparing molded product of thermochromic polyvinyl chloride MATUI SHIKISO CHEMICAL CO., LTD. (JP) 1989-05-02 US disclosed
US-4616024-A Dihydropyridine anti-ischaemic and antihypertensive agents PFIZER INC. (US) 1986-10-07 US disclosed
EP-0100189-B1 DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS Pfizer Limited (GB) 1986-05-28 EP disclosed
US-4515799-A Dihydropyridine anti-ischaemic and antihypertensive agents PFIZER INC. (US) 1985-05-07 US disclosed
EP-0100189-A2 Dihydropyridine anti-ischaemic and antihypertensive agents Pfizer Limited (GB) 1984-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 KMT2A 2634/4885ALDH1A1 164/4885MEN1 2823/4885
US-12024524-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 KMT2A 2634/4885ALDH1A1 164/4885MEN1 2823/4885
US-12264138-B2 Process for the preparation of microbiocidal oxadiazole derivatives CYP51A1, MPO, NOX5 KMT2A 4305/4885ALDH1A1 258/4885MEN1 3852/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR KMT2A 3227/4885ALDH1A1 4757/4885MEN1 722/4885
US-20240376085-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 IL17A, IL23R, IL4I1 KMT2A 2647/4885ALDH1A1 201/4885MEN1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.